Centene (CNC) is trading higher as investors key in on the company’s intact 2026 earnings recovery narrative—centered on adjusted diluted EPS guidance of greater than $3.00—and the idea that marketplace (ACA) margins can improve as pricing actions flow through. The move follows recent investor-focused updates and market chatter that Centene’s pricing discipline and cost trajectory can stabilize results after last year’s marketplace and Medicaid volatility.

Centene’s most recent formal outlook calls for 2026 adjusted diluted EPS of greater than $3.00, alongside GAAP diluted EPS of greater than $1.98. In its latest annual results release, Centene reported full-year 2025 adjusted diluted EPS of $2.08 and a full-year GAAP diluted loss per share of $(13.53), underscoring why the market is highly sensitive to any evidence the reset year is over and margins are rebuilding.

At roughly the high-$30s/low-$40s share-price area, CNC remains priced as a turnaround story, so incremental confidence—especially around ACA exchange profitability and Medicaid cost trend control—can drive outsized percentage moves. Traders are also positioning for follow-through from management’s cost actions taken in the back half of 2025 and for clearer visibility into 2026 exchange performance as enrollment, pricing, and risk-adjustment dynamics become more measurable through the year.

Key near-term swing factors include updates on marketplace pricing and risk-adjustment expectations, Medicaid medical cost trend and rate adequacy, and any additional management commentary that tightens the range of 2026 outcomes around the >$3.00 adjusted EPS target. Investors will also watch for incremental analyst actions (upgrades/price-target changes) tied to ACA margin assumptions and evidence that 2026 profitability improvement is translating into cleaner quarterly execution.